Investment
Features
FeesSafety
Academy
More
Pluang+

Janus Living raises $2.15B to acquire senior housing amid strong demand and minimal new supply.

Market News
18 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Janus Living (JAN) raised $2.15 billion through equity issuance to capitalize on the senior housing sector, which is experiencing strong capital inflows but minimal new development. This unique market condition allows JAN to acquire properties at attractive cap rates, boosting its adjusted funds from operations per share (AFFO/share). With almost no debt and a $5 billion acquisition capacity, JAN is positioned to benefit from rising property values as cap rates decline, making its current acquisitions more valuable. The sector's limited new supply and strong demand driven by an aging population and financial strength create a favorable environment for sustained growth in senior housing.

More News

Grocery Outlet posts Q2 revenue growth and beats EPS forecasts amid strategic restructuring.

Grocery Outlet posts Q2 revenue growth and beats EPS forecasts amid strategic restructuring.

Grocery Outlet Holding Corp. reported a 1.1% revenue increase to $1.19 billion in Q2 2026 and an adjusted EPS of $0.20, beating analyst expectations despite a 13% EPS decline. The company is undergoing strategic restructuring, including closing 36 un...

Company Fundamentals
Bullish
1 hour ago
Hesai posts revenue beat and 60% net income growth despite EPS miss in Q2 2026

Hesai posts revenue beat and 60% net income growth despite EPS miss in Q2 2026

Hesai Group reported Q2 2026 earnings with revenue of $126.9 million, slightly above expectations, driven by strong LiDAR sales. Despite an EPS of $0.01 missing the $0.08 estimate, the company achieved its fifth consecutive GAAP profitable quarter, w...

Company Fundamentals
Bullish
1 hour ago
Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.

Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.

Amylyx Pharmaceuticals' stock surged 54.43% after its drug avexitide showed positive Phase 3 trial results, cutting hypoglycemic events by 55% in post-bariatric patients. UBS set a $45 price target, implying a 36% upside from current levels. The stoc...

Market News
Bullish
3 hours ago
Ondas boosts growth with Aran Defense acquisition and strong Q2 revenue, raising 2026 outlook.

Ondas boosts growth with Aran Defense acquisition and strong Q2 revenue, raising 2026 outlook.

Ondas is expanding its market and technology through acquiring Aran Defense Ltd., enhancing its autonomous and defense systems. The company reported record Q2 revenue of $83.8 million, up 67% from the previous quarter and over 13 times year-over-year...

Company Fundamentals
Bullish
3 hours ago
Kennametal adds Dawne Hickton and Richard Harshman to its Board for strategic growth.

Kennametal adds Dawne Hickton and Richard Harshman to its Board for strategic growth.

Kennametal Inc. has appointed Dawne S. Hickton and Richard J. Harshman to its Board of Directors, bringing significant leadership and industry expertise in aerospace, defense, and materials. Hickton leads Cumberland Additive and has extensive experie...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App